Corvus Pharmaceuticals, Inc. Capital Expenditures Incurred but Not yet Paid
Corvus Pharmaceuticals, Inc. (CRVS) reported Capital Expenditures Incurred but Not yet Paid of $188.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2019-03-31 was $16.00K.
- Corvus Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2018-12-31 was $78.00K.
- Corvus Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2017-03-31 was $46.00K, a 76.88% decline year-over-year.
- Corvus Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for the quarter ending 2016-12-31 was -$38.00K, a 129.69% decline year-over-year.
- Corvus Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $5.00K.
- Corvus Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2018 was $84.00K.
- Corvus Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2016 was $84.00K, a 70.63% decline from fiscal 2015.
- Corvus Pharmaceuticals, Inc. capital expenditures incurred but not yet paid for fiscal 2015 was $286.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $188.00K 10-Q · filed 2026-08-06 | |||
| 2022-06-30 | $251.00K 10-Q · filed 2022-08-08 | |||
| 2021-12-31 | $5.00K 10-K · filed 2024-03-19 | |||
| 2019-03-31 | $16.00K 10-Q · filed 2020-04-30 | $94.00K derived: sum of 2 quarters · filed 2021-03-25 | ||
| 2018-12-31 | $78.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $84.00K 10-K · filed 2021-03-25 | ||
| 2018-09-30 | $6.00K 10-Q · filed 2019-10-29 | |||
| 2017-09-30 | $48.00K 10-Q · filed 2017-11-02 | |||
| 2017-03-31 | $46.00K 10-Q · filed 2018-05-03 | $8.00K derived: sum of 2 quarters · filed 2019-03-07 | $119.00K derived: sum of 3 quarters · filed 2019-03-07 | -$69.00K derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | -$38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $73.00K derived: sum of 2 quarters · filed 2019-03-07 | -$115.00K derived: sum of 3 quarters · filed 2019-03-07 | $84.00K 10-K · filed 2019-03-07 |
| 2016-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$77.00K derived: sum of 2 quarters · filed 2017-11-02 | $122.00K 10-Q · filed 2017-11-02 | $250.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | -$188.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $11.00K 10-Q · filed 2017-08-03 | $139.00K derived: sum of 3 quarters · filed 2018-03-01 | $288.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-03-31 | $199.00K 10-Q · filed 2017-05-04 | $327.00K derived: sum of 2 quarters · filed 2018-03-01 | $476.00K derived: sum of 3 quarters · filed 2018-03-01 | $425.00K derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $277.00K derived: sum of 2 quarters · filed 2018-03-01 | $226.00K derived: sum of 3 quarters · filed 2018-03-01 | $286.00K 10-K · filed 2018-03-01 |
| 2015-09-30 | $149.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $98.00K derived: sum of 2 quarters · filed 2016-11-03 | $158.00K 10-Q · filed 2016-11-03 | |
| 2015-06-30 | -$51.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $9.00K 10-Q · filed 2016-08-04 | ||
| 2015-03-31 | $60.00K 10-Q · filed 2016-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |